Radiomics in sarcoma trials: a complement to RECIST for patient assessment

Abstract

Radiological imaging has a critical role in the diagnosis of sarcomas and in evaluating therapy response assessment. The current gold standard for response assessment in solid tumors is the Response Evaluation Criteria in Solid Tumors, which evaluates changes in tumor size as a surrogate endpoint for therapeutic efficacy. However, tumors may undergo necrosis, changes in vascularization or become cystic in response to therapy, with no significant volume changes; thus, size assessments alone may not be adequate. Such morphological changes may give rise to radiographic phenotypes that are not easily detected by human operators. Fortunately, recent advances in high-performance computing and machine learning algorithms have enabled deep analysis of radiological images to extract features that can provide richer information about intensity, shape, size or volume, and texture of tumor phenotypes. There is growing evidence to suggest that these image-derived or “radiomic features” are sensitive to biological processes such as necrosis and glucose metabolism. Thus, radiomics could prove to be a critical tool for assessing treatment response and may present an integral complement to existing response criteria, opening new avenues for patient assessment in sarcoma trials.

Keywords

Clinical trials / response assessment / radiology / radiomics / machine learning

References

[1] Jaffe CC.Response assessment in clinical trials: implications for sarcoma clinical trial design.Oncologist2008;13:14-8

[2] Ko CC,Kuo YT.Imaging biomarkers for evaluating tumor response: RECIST and beyond.Biomark Res2021;9:52 PMCID:PMC8252278

[3] Therasse P.Measuring the clinical response: what does it mean?.Eur J Cancer2002;38:1817-23

[4] Palmer MK.WHO handbook for reporting results of cancer treatment.Br J Cancer1982;45:484-5

[5] Nishino M,Ramaiya NH.Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know.AJR Am J Roentgenol2010;195:281-9

[6] Therasse P,Eisenhauer EA.New guidelines to evaluate the response to treatment in solid tumors.Breast Cancer2005;12:S16-27

[7] Eisenhauer EA,Bogaerts J.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009;45:228-47

[8] Fanciullo C,Carlicchi E,Messina C.Radiomics of musculoskeletal sarcomas: a narrative review.J Imaging2022;8:45 PMCID:PMC8876222

[9] Benjamin RS,Macapinlac HA.We should desist using RECIST, at least in GIST.J Clin Oncol2007;25:1760-4

[10] Choi H,Faria SC.Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.J Clin Oncol2007;25:1753-9

[11] Aerts HJ,Leijenaar RT.Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach.Nat Commun2014;5:4006 PMCID:PMC4059926

[12] Lambin P,Leijenaar R.Radiomics: extracting more information from medical images using advanced feature analysis.Eur J Cancer2012;48:441-6 PMCID:PMC4533986

[13] Avanzo M,Stancanello J.Machine and deep learning methods for radiomics.Med Phys2020;47:e185-202 PMCID:PMC8965689

[14] Sharp G,Pekar V.Vision 20/20: perspectives on automated image segmentation for radiotherapy.Med Phys2014;41:050902 PMCID:PMC4000389

[15] Reiazi R,Famiyeh P.The impact of the variation of imaging parameters on the robustness of computed tomography radiomic features: a review.Comput Biol Med2021;133:104400

[16] Cardenas CE,Anderson BM,Brock KB.Advances in auto-segmentation.Semin Radiat Oncol2019;29:185-97

[17] Tian F,Kambadakone AR.Response assessment to neoadjuvant therapy in soft tissue sarcomas: using CT texture analysis in comparison to tumor size, density, and perfusion.Abdom Imaging2015;40:1705-12

[18] Escobar T,Orlhac F.Voxel-wise supervised analysis of tumors with multimodal engineered features to highlight interpretable biological patterns.Med Phys2022;49:3816-29 PMCID:PMC9325536

[19] Vallières M,Skamene SR.A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities.Phys Med Biol2015;60:5471-96

[20] Crombé A,Guigui J,Buy X.Influence of temporal parameters of DCE-MRI on the quantification of heterogeneity in tumor vascularization.J Magn Reson Imaging2019;50:1773-88

[21] Lambin P,Deist TM.Radiomics: the bridge between medical imaging and personalized medicine.Nat Rev Clin Oncol2017;14:749-62

[22] Nardone V,Grassi R.Delta radiomics: a systematic review.Radiol Med2021;126:1571-83

[23] Crombé A,Kind M.T₂-based MRI delta-radiomics improve response prediction in soft-tissue sarcomas treated by neoadjuvant chemotherapy.J Magn Reson Imaging2019;50:497-510

[24] Lin P,Chen S.A Delta-radiomics model for preoperative evaluation of Neoadjuvant chemotherapy response in high-grade osteosarcoma.Cancer Imaging2020;20:7 PMCID:PMC6958668

[25] Gao Y,Hsu W.Treatment effect prediction for sarcoma patients treated with preoperative radiotherapy using radiomics features from longitudinal diffusion-weighted MRIs.Phys Med Biol2020;65:175006

[26] Sanduleanu S,de Jong EEC.Tracking tumor biology with radiomics: a systematic review utilizing a radiomics quality score.Radiother Oncol2018;127:349-60

[27] Zwanenburg A,Abdalah MA.The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping.Radiology2020;295:328-38 PMCID:PMC7193906

[28] van Griethuysen JJM,Parmar C.Computational radiomics system to decode the radiographic phenotype.Cancer Res2017;77:e104-7 PMCID:PMC5672828

[29] Shaikh FA,Awan O.Technical challenges in the clinical application of radiomics.JCO Clin Cancer Inform2017;1:1-8

[30] Timmeren JE, Cester D, Tanadini-Lang S, Alkadhi H, Baessler B. Radiomics in medical imaging-“how-to” guide and critical reflection.Insights Imaging2020;11:91 PMCID:PMC7423816

[31] Ibrahim A,Beuque M.Radiomics for precision medicine: current challenges, future prospects, and the proposal of a new framework.Methods2021;188:20-9

[32] Tang C,Amer A.Development of an immune-pathology informed radiomics model for non-small cell lung cancer.Sci Rep2018;8:1922 PMCID:PMC5792427

[33] Tunali I.Hypoxia-related radiomics predict immunotherapy response: a multi-cohort study of NSCLC.bioRxiv2020;020859

[34] Tinoco G,Hoyd R.The sarcoma microbiome as a diagnostic and therapeutic target.JCO2021;39:11541

[35] Madanat-Harjuoja LM,Lu Y.Circulating tumor DNA is associated with response and survival in patients with advanced leiomyosarcoma.Clin Cancer Res2022;28:2579-86